Morphea Clinical Trials and Treatments

Morphea is a localized form of scleroderma centered on the skin and the tissue beneath it, which in deep and linear forms can extend to fascia, muscle and bone, without the systemic manifestations characteristic of systemic sclerosis (systemic sclerosis primarily affects internal organs). The pathophysiology involves excessive collagen deposition in the dermis and subcutaneous tissues, mediated by transforming growth factor-beta (TGF-β) and other fibrogenic cytokines, with activation of fibroblasts and myofibroblasts. Morphea presents as circumscribed patches of induration with characteristic lilac ring (reddish-purple border) in early stages.

The most common symptoms of Morphea include Hardened, thickened patches of skin with well-defined borders, Purple or reddish rings around patches (lilac ring sign), Hypopigmentation or hyperpigmentation of affected areas, Skin tightness and loss of normal skin texture, Itching or burning sensations, among others. About 0.4 to 2.7 new cases per 100,000 people each year; by age 80 about 2 in 1,000 people have had it (Peterson et al., J Rheumatol 1997). More common in women than men. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Morphea from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Morphea is exploring multiple approaches to slow and potentially reverse skin fibrosis before it causes lasting dysfunction. Doctors treat morphea mostly with medicines approved for other conditions.

As of October 21, 2026, no current FDA drug label names Morphea as a condition the drug treats.

The exact cause of Morphea is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Localized scleroderma is autoimmune and not passed from parent to child; no gene test exists. About 0.4 to 2.7 new cases per 100,000 people each year; by age 80 about 2 in 1,000 people have had it (Peterson et al., J Rheumatol 1997). More common in women than men. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Morphea. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Localized scleroderma is autoimmune and not passed from parent to child; no gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Morphea clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Morphea clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.